AlphaGrep UK Ltd’s ImmunityBio IBRX Stock Holding History

AlphaGrep UK Ltd’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,539	Closed	-$22.8K	–	856
2025 Q4	$22.8K	Buy	+11,539	New	+$26.1K	0.01%	657

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

AlphaGrep UK Ltd's IBRX Position: Q1 2026 in Review

AlphaGrep UK Ltd sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 11,539 shares — an estimated $22.8K sold.

AlphaGrep UK Ltd first reported a position in IBRX in Q4 2025 and held it in 1 quarter. The position peaked at $22.8K in Q4 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

AlphaGrep UK Ltd reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
AlphaGrep UK Ltd sold 11,539 ImmunityBio shares in Q1 2026, an estimated $22.8K.
AlphaGrep UK Ltd first reported a position in ImmunityBio in Q4 2025 and held it in 1 quarter.
AlphaGrep UK Ltd's ImmunityBio position peaked at $22.8K in Q4 2025.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.